- Conditions
- Sickle Cell Disease
- Interventions
- TAK-755, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 677
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Crohn's Disease
- Interventions
- Placebo matching with BMS-945429, BMS-945429
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 8
- States / cities
- La Jolla, California • San Diego, California • Lone Tree, Colorado + 5 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Placebo, Ocrelizumab, Avonex
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
- Conditions
- Breakthrough Pain
- Interventions
- Inhaled Placebo, Inhaled Fentanyl 25 mcg, Intravenous Fentanyl 25 mcg, Inhaled Fentanyl 25 mcg x 2, Inhaled Fentanyl 25 mcg x 4, Inhaled Fentanyl 25 mcg x 6, Inhaled Fentanyl 25 mcg x 12
- Drug
- Lead sponsor
- Alexza Pharmaceuticals, Inc.
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Interventions
- Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
- Other · Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Cypress, California • Glendale, California • Denver, Colorado + 4 more
- Conditions
- Chronic Cluster Headache
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 28 more
- Conditions
- Healthy
- Interventions
- PF-07264660 intravenous single ascending dose, PF-07264660 subcutaneous multiple ascending dose, Intravenous placebo, subcutaneous placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Garden Grove, California • Long Beach, California • Los Alamitos, California + 3 more
- Conditions
- Healthy
- Interventions
- LY3461767 - SC, LY3461767 - IV, Placebo - SC
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas
- Conditions
- COVID-19
- Interventions
- RDV, Placebo to Match RDV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 92
- States / cities
- Chandler, Arizona • Tucson, Arizona • Eureka, California + 78 more
- Conditions
- Healthy
- Interventions
- HFB30132A, Placebo
- Drug · Other
- Lead sponsor
- HiFiBiO Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Hypercholesterolemia, Dyslipidemia
- Interventions
- Placebo, Statin, PF-04950615 (RN316), Satin
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 38
- States / cities
- Tustin, California • Walnut Creek, California • Clearwater, Florida + 25 more
- Conditions
- Asthma
- Interventions
- MN-221, Placebo
- Drug
- Lead sponsor
- MediciNova
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 4
- States / cities
- Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more
- Conditions
- HIV-1-infection
- Interventions
- 3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo
- Biological
- Lead sponsor
- International AIDS Vaccine Initiative
- Network
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Seattle, Washington
- Conditions
- Acute Ischemic Stroke
- Interventions
- natalizumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 19
- States / cities
- San Diego, California • Gainesville, Florida • Kansas City, Kansas + 16 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- JK07, Matching Placebo
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Stanford, California • Boston, Massachusetts • Rochester, Minnesota + 4 more
- Conditions
- SARS-CoV2 Infection, COVID-19
- Interventions
- IMM-BCP-01, Placebo
- Drug
- Lead sponsor
- Immunome, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Long Beach, California • Miami Lakes, Florida • New York, New York
- Conditions
- Alzheimer Disease
- Interventions
- ALIA-1758, Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Rheumatoid Arthritis, Pharmacokinetics of ASP2409
- Interventions
- ASP2409, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 10
- States / cities
- Anniston, Alabama • Costa Mesa, California • Clearwater, Florida + 7 more
- Conditions
- Malaria, Malaria, Cerebral
- Interventions
- Intravenous artesunate
- Drug
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Patients With Acute Pancreatitis
- Interventions
- Dexamethasone acetate, Placebo
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COVID-19
- Interventions
- REGN10933+REGN10987 combination therapy, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 57
- States / cities
- Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 48 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Tecemotide, Placebo, Cyclophosphamide (CPA), Saline (sodium chloride)
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Hepatitis C
- Interventions
- MDX1106-02, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Anaheim, California • San Francisco, California • Springfield, Illinois + 4 more
- Conditions
- Multiple Sclerosis, Primary Progressive
- Interventions
- Ocrelizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,013 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Clearwater, Florida • Orlando, Florida + 5 more